3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
29
Fallopian Tube Neoplasms
15
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
6
Peritoneal Neoplasms
3
Multiple Myeloma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Kaposi
1
Pelvic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Genital Neoplasms, Female
1
Genetic Predisposition to Disease
1
Endometrial Neoplasms
1
Carcinoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled